CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗多发性骨髓瘤的当前应用
英文原题：Current use of CAR T cells to treat multiple myeloma.
查看英文原题
Current use of CAR T cells to treat multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
美国FDA目前批准的抗B细胞成熟抗原（BCMA）嵌合抗原受体（CAR）T细胞疗法，显著改善了既往接受多线治疗、对传统蛋白酶体抑制剂、免疫调节药物和抗CD38单克隆抗体耐药的多发性骨髓瘤患者临床结局。然而，尽管治疗取得进展，多发性骨髓瘤仍是无法治愈的血液系统恶性肿瘤。本综述讨论目前FDA批准CAR-T 疗法的临床应用考量，包括评估这些药物用于更早治疗线的新数据；并讨论抗BCMA CAR-T 治疗后复发患者的管理问题，这仍是尚未满足的临床需求。
展开英文摘要原文
Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapies currently approved by the US Food and Drug Administration (FDA) have dramatically improved clinical outcomes for patients with heavily pretreated multiple myeloma who have disease refractory to conventional proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies.
However, despite this progress, multiple myeloma remains an incurable hematologic malignancy. In this review, we discuss practical considerations for currently FDA approved CAR T-cell therapies, including newer data evaluating those agents in earlier lines of therapy.
We also discuss considerations for patients following relapse from anti-BCMA CAR T-cell therapy, which currently represents an unmet clinical need.
论文信息
- 作者
- Firestone RS、Mailankody S
- 第一作者单位
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.United States
- 通讯作者单位
- Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY.United States
- 文献类型
- 综述
- 期刊
- Hematology. American Society of Hematology. Education Program2023 Dec 8
- 原文标识
- PubMed 38066841 · DOI 10.1182/hematology.2023000434
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →